Table 2.

Weighted prevalence of e-cigarette use among adult patients and survivors of smoking-related cancersa in the United States: National Health Interview Survey 2014–2017

Variable%95% CIPb
Age<0.001
 18–44 years6.283.17–9.39
 45–64 years5.083.46–6.70
 ≥65 years1.050.53–1.57
Gender0.047
 Male2.301.29–3.31
 Female3.872.74–4.99
Race/ethnicity0.241
 Non-Hispanic White3.502.58–4.43
 Non-Hispanic Black1.350.22–2.48
 Hispanic2.340.05–4.63
 Other2.110.00c–5.03
Marital status0.533
 Married/living with partner2.871.84–3.90
 Widowed/divorced/separated3.752.44–5.06
 Never married3.490.95–6.04
Regiond0.237
 Northeast2.340.81–3.87
 Midwest3.862.25–5.47
 South3.742.25–5.22
 West2.090.91–3.26
Survey year0.697
 20143.772.16–5.37
 20152.481.04–3.92
 20163.011.43–4.59
 20173.431.95–4.92
Time since cancer diagnosis0.849
 Less than 2 years3.090.91–5.26
 2 years to less than 5 years2.630.80–4.45
 5 years or more3.242.35–4.13
Alcohol use0.027
 Lifetime abstainer1.280.31–2.25
 Former drinker2.851.47–4.23
 Current light/moderate drinker3.642.46–4.81
 Current heavy drinker6.441.59–11.30
Smoking status<0.001
 Never smoker0.240.00c–0.61
 Former smoker2.181.17–3.19
 Current smoker11.638.28–14.98
Cigarette quantitye0.841
 <1 pack per day11.357.27–15.43
 ≥1 pack or more per day12.066.25–17.87
One or more quit attempts in prior yeare0.946
 No11.346.43–16.25
 Yes11.577.11–16.04
Overall study population3.182.40–3.96
  • aSmoking-related cancers defined as cancers of the bladder, cervix, colon, esophagus, kidney, larynx (windpipe), liver, lung, mouth/tongue/lip, pancreas, rectum, stomach, and throat (pharynx).

  • bP value for χ2 tests of homogeneity between e-cigarette exposure and potential predictor variable.

  • cLower bound of calculated confidence interval less than 0%.

  • dRegions as defined by the U.S. Census Bureau.

  • eSubpopulation defined by cancer patients and survivors who were current smokers at the time of the interview.